LION bioscience releases SRS Pathway Editor.

CAMBRIDGE, England -- LION bioscience announced today the release and immediate availability of the SRS Pathway Editor. This new software allows researchers to produce, visualize, compare and merge biological pathway and other relationship data using a novel, proprietary algorithm. The SRS Pathway Editor was built on evolving industry standards such as the widely used Eclipse(TM) platform and SBML, the standard format for importing and exporting pathways.

The SRS Pathway Editor utilizes SRS Web Service technology to pull data from many different data sources and visualize the relationships between the different data points. This can include data from public domain sources (e.g. KEGG, BIND), proprietary data and text mining results extracted from literature. The SRS Pathway Editor provides a standardized view across diverse data. The user can then modify or curate the data as well as overlay additional information (e.g. gene expression results) onto the pathway.

"The SRS Pathway Editor capitalizes on SRS integration capabilities. Linking relevant information together and visualizing the relationship networks will help researchers to understand the interdependencies and allow them to make informed decisions", said Dr. Thure Etzold, CEO of LION bioscience. "The SRS Pathway Editor can also be used as a standalone desktop tool, loading data from many different data sources outside of SRS."

About SRS

SRS is a proven, scalable and robust data integration platform that provides fast access to diverse life sciences data - genetic, protein, cellular, molecular and clinical -- from public and proprietary sources, regardless of data format. SRS is used in more than 300 commercial and academic sites delivering genomic data daily to thousands of users around the globe. SRS is the market leader for bioinformatics data integration, providing global bioinformatics platforms for pharmaceutical companies such as Eli Lilly, Johnson & Johnson and AstraZeneca, as well as the preferred search engine for genomics portals from leading data providers such as Celera, Incyte and Derwent.

Eclipse is a trademark of Eclipse Foundation, Inc.

About LION bioscience

LION bioscience (ISIN: DE0005043509, Reuters: LIOG, Bloomberg: LIO) provides proven information and knowledge management solutions to significantly improve life science R&D performance and productivity. Since it was founded in 1997, the company has become a recognized leader in the area of bioinformatics. LION has operations worldwide in Heidelberg, Germany, Cambridge, UK and Cambridge, MA, USA. LION's products are distributed by CTC Laboratory Systems in Japan and DigiGenomics in Taiwan. LION's (http://www.lionbioscience.com) solutions are used by more than 27,000 researchers at 300 academic and industrial customers globally.

Except for the historical information contained herein, the matters set forth in this press release are forward looking within the meaning of the Private Securities Litigation Reform Act of 1995, and other applicable U.S. and German laws. These forward-looking statements may include projections, assumptions, estimates, targets, and descriptions of future events. Such statements are based on currently available information and on LION's current expectations as to future events that may not prove to be accurate. These statements are not guarantees of future performance and involve risks and uncertainties that are difficult to predict. Many factors could cause the actual results, performance or achievements of LION to be materially different from those that may be projected, expected, targeted, expressed or implied by such statements. All roll-out plans and future dates with respect to completion of development and market release of LION products are target dates only based on the company's current planning and may change in the future. Any delays in the current product release schedule will have a materially adverse effect on the company's targets for fiscal year. We refer you to LION's Annual Reports on Form 20-F, as recently filed with the Securities and Exchange Commission (SEC) on September 30, 2004 (Form 20-F), in which these and other risk factors are discussed. In the event of any material conflicts between the two documents, Form 20-F should be relied on. LION expressly disclaims any obligation or undertaking to release publicly any updates, revisions or corrections to any forward-looking statements or historical information contained in this announcement, whether as a result of new information, change of assumptions or business model, future developments or otherwise.